Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266628 · ClinicalTrials.gov registry record · Phase 2
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,599
- Enrollment target
NCT02266628 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 1,599 participants.
The verdict
NCT02266628, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,599 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of the RSV- F Vaccine in elderly subjects, as well as rate the incidence of medically- attended RSV disease in vaccine and placebo recipients.
Interventions
- BIOLOGICAL RSV-F Vaccine
- BIOLOGICAL Saline Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,599 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02266628
The ClinicalTrials.gov registry entry for NCT02266628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,599 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RSV-F Vaccine is the first listed.
NCT02266628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02266628 about?
NCT02266628 is a clinical study titled "Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults". The purpose of this study is to evaluate the safety and immunogenicity of the RSV- F Vaccine in elderly subjects, as well as rate the incidence of medically- attended RSV disease in vaccine and placebo recipients.
What is the current status of trial NCT02266628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,599 participants. The study started on 2014-10. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02266628?
The interventions under investigation include: RSV-F Vaccine (BIOLOGICAL), Saline Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02266628?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.